A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

NCT01009073 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: ABT-263
DRUG: erlotinib
DRUG: irinotecan (3-week schedule)
DRUG: irinotecan (weekly schedule)

Sponsor

AbbVie (prior sponsor, Abbott)